Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue (Details Textual)

v3.24.3
Note 3 - Revenue (Details Textual)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 31, 2023
USD ($)
Jan. 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2017
May 19, 2021
USD ($)
Feb. 08, 2018
May 02, 2017
Increase in Contract With Customer Liability     $ 0     $ 0              
Decrease in Contract with Customer, Liability     $ 0 $ 17,100   $ 0 $ 38,700            
Amendment of the Second Seagen Amendment [Member]                          
Revenue from Contract with Customer, Excluding Assessed Tax               $ 10,100          
Genentech [Member]                          
Number Of Initial Research Programs                     2    
Contract with Customer, Liability, Revenue Recognized         $ 12,500                
Number Of Optional Additional Research Programs                     2    
B P Assets X I I Inc [Member] | Exclusive Product License Agreement [Member]                          
Contract with Customer, Milestone Payment Received $ 2,500                        
Seattle Genetics Inc. [Member] | License and Collaboration Agreement [Member]                          
Number of Research Programs                       3  
Seattle Genetics Inc. [Member] | Collaborative Arrangement [Member]                          
Revenue from Contract with Customer, Excluding Assessed Tax   $ 5,000             $ 5,000        
Astra Zeneca A B [Member] | License and Collaboration Agreement [Member]                          
Contract with Customer, Liability, Revenue Recognized         $ 4,000                
Contract with Customer, Liability, Current       $ 3,500     $ 3,500            
Astra Zeneca A B [Member] | License and Collaboration Agreement [Member] | Maximum [Member]                          
Number of Collaboration Products                         4
Astra Zeneca A B [Member] | License and Collaboration Agreement [Member] | Minimum [Member]                          
Number of Collaboration Products                         2
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]                          
Number of Novel Proteins                   1      
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member] | License and Collaboration Agreement [Member]                          
Contract with Customer, Liability, Current               $ 4,700          
Number of Programs                   5      
License [Member] | Genentech [Member]                          
Contract with Customer, Liability, Total                     $ 20,000